Phase II study of antineoplastons A10 and AS2-1 in adult patients with primary malignant brain tumors
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- Sponsors Burzynski Research Institute
- 22 Oct 2008 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by CT.gov
- 12 Aug 2005 New trial record.